These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24237936)

  • 21. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.
    González-Ortega E; Mena MP; Permanyer M; Ballana E; Clotet B; Esté JA
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4487-92. PubMed ID: 20643898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
    Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
    Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
    Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
    Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
    Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.
    Parajuli B; Acharya K; Bach HC; Parajuli B; Zhang S; Smith AB; Abrams CF; Chaiken I
    Biochem J; 2018 Mar; 475(5):931-957. PubMed ID: 29343613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
    Nguyen AT; Feasley CL; Jackson KW; Nitz TJ; Salzwedel K; Air GM; Sakalian M
    Retrovirology; 2011 Dec; 8():101. PubMed ID: 22151792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking HIV-1 entry by a gp120 surface binding inhibitor.
    Tsou LK; Chen CH; Dutschman GE; Cheng YC; Hamilton AD
    Bioorg Med Chem Lett; 2012 May; 22(9):3358-61. PubMed ID: 22487177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.
    Fontana J; Keller PW; Urano E; Ablan SD; Steven AC; Freed EO
    J Virol; 2016 Jan; 90(2):972-8. PubMed ID: 26537676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of anti-HIV activity of succinylated human serum albumin.
    Kuipers ME; vd Berg M; Swart PJ; Laman JD; Meijer DK; Koppelman MH; Huisman H
    Biochem Pharmacol; 1999 Apr; 57(8):889-98. PubMed ID: 10086322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 Gag, Envelope, and Extracellular Determinants Cooperate To Regulate the Stability and Turnover of Virological Synapses.
    Gardiner JC; Mauer EJ; Sherer NM
    J Virol; 2016 Jul; 90(14):6583-6597. PubMed ID: 27170746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obstruction of HIV-1 particle release by interferon-alpha occurs before viral protease processing and is independent of envelope glycoprotein.
    Babé LM; Unal A; Craik CS
    J Interferon Cytokine Res; 1997 May; 17(5):287-93. PubMed ID: 9181467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition.
    Majerle A; Pristovsek P; Mancek-Keber M; Jerala R
    J Biol Chem; 2011 Jul; 286(29):26228-37. PubMed ID: 21636577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
    Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
    Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of resistance to a potent D-peptide HIV entry inhibitor.
    Smith AR; Weinstock MT; Siglin AE; Whitby FG; Francis JN; Hill CP; Eckert DM; Root MJ; Kay MS
    Retrovirology; 2019 Oct; 16(1):28. PubMed ID: 31640718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
    Berinyuy E; Soliman ME
    J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.